GeneTx and Ultragenyx (RARE) Announce Positive Interim Phase 1/2 Data on Investigational GTX-102 Demonstrating Improvement in Patients with Angelman Syndrome
Go back to GeneTx and Ultragenyx (RARE) Announce Positive Interim Phase 1/2 Data on Investigational GTX-102 Demonstrating Improvement in Patients with Angelman Syndrome| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 35.98 +2.28 (6.77%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $33.70 | 52 Week High | $117.12 | |||
| Open | $34.19 | 52 Week Low | $46.52 | |||
| Day High | $36.57 | P/E | N/A | |||
| Day Low | $33.57 | EPS | $-1.97 | |||
| Volume | 1,843,483 | |||||
